Evidence map›Paper›PMID 42204346›Full record

ArticleEMBO reports2026

Poorly perfused tumor regions harbor T cells with a glucose-dependent effector phenotype.

Marta Riera-Borrull, Víctor Cerdán Porqueras, Sonia Tejedor Vaquero, Claudia Tomaselli González, Mauricio Guzmán, Donata Martinuzzi, Diego Ceacero-Heras, Andrea Cerutti, Jose Aramburu, Cristina López-Rodríguez

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta Riera-Borrull *Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0003-4670-7290
Víctor Cerdán Porqueras *Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-3711-0057
Sonia Tejedor Vaquero *Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0003-2873-4981
Claudia Tomaselli GonzálezDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0009-0001-7140-9909
Mauricio GuzmánTranslational Clinical Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain.ORCID 0000-0002-4447-2064
Donata MartinuzziTranslational Clinical Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain.ORCID 0009-0001-4780-7456
Diego Ceacero-HerasDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0003-1048-5905
Andrea CeruttiTranslational Clinical Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain.ORCID 0000-0003-3026-4704
Jose AramburuDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. jose.aramburu@upf.edu.ORCID 0000-0001-9279-9523
Cristina López-RodríguezDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. cristina.lopez-rodriguez@upf.edu.ORCID 0000-0002-2311-2406

Funding

Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) 2021SGR00683Institució Catalana de Recerca i Estudis Avançats (ICREA) ICREA Academia 2014 and 2022MEC | Agencia Estatal de Investigación (AEI) PID2021-128721OB-I00MEC | Agencia Estatal de Investigación (AEI) PID2024-155263OB-I00MEC | Agencia Estatal de Investigación (AEI) PID2024-159862OB-I00MEC | Agencia Estatal de Investigación (AEI) PRE2022-102056MEC | Agencia Estatal de Investigación (AEI) RTI2018-095902-B-I00MEC | Agencia Estatal de Investigación (AEI) RYC2021-032169-IMEC | Agencia Estatal de Investigación (AEI) Unidad de Excelencia María de Maeztu,CEX2018-000792-MMEC | Agencia Estatal de Investigación (AEI) Unidad de Excelencia Maria de Maeztu. CEX2024-001431-MMinisterio de Economía y Competitividad (MEC) BES-2013-062670Ministerio de Universidades (MU) FPU19-04119Worldwide Cancer Research (WCR) 20-0144
6 · The paper itself

Abstract

Effector T lymphocytes are avid nutrient consumers, but can function in nutrient-poor tumor microenvironments. Availability of key nutrients such as glucose inside the tumor is not homogeneous, and how tumor-infiltrating T lymphocytes (TILs) differ between regions with better and poorer blood perfusion is not well known. Here we show that in vitro-stimulated TILs can induce substantial production of hallmark glucose-dependent cytokines under glucose concentrations 20 times lower than in blood. In vivo, effector TILs in tumor regions with poor access to blood show comparable capacity for inducing IFNγ and granzyme B to TILs with fuller accessibility; exhibit an enhanced type I IFN response supported by local myeloid cells; and unexpectedly, have reduced expression of immune checkpoint and Treg-associated markers. TILs with poor blood accessibility also have lower biosynthetic activity than highly blood-accessible TILs, yet both compartments depend fundamentally on glucose for ATP production. Thus, effector T lymphocytes in poorly perfused tumor regions can maintain specific glucose-dependent responses, and might be partially protected from inhibitory and exhausting pressure from the tumor microenvironment.

Indexed as

GlucoseLymphocytes, Tumor-InfiltratingT-LymphocytesAnimalsCytokinesGranzymesHumansInterferon-gammaMicePhenotypeTumor MicroenvironmentCytokinesGlucoseGranzymesInterferon-gamma

Identifiers

PMID42204346
PMCPMC13303879

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.